Key result
Human leukocyte antigen alleles showed no difference between small-cell lung cancer patients with and without the anti-Hu syndrome, suggesting specific haplotypes are not required for its development.
Why the study?
Are specific human leukocyte antigen alleles associated with the development of anti-Hu syndrome in patients with small-cell lung cancer?
Case-Control (n=47)
Are specific human leukocyte antigen alleles associated with the development of anti-Hu syndrome in patients with small-cell lung cancer?
Specific HLA haplotypes do not appear to be required for the development of the anti-Hu syndrome in patients with small-cell lung cancer.
HLA typing unlikely to stratify anti-Hu risk in SCLC; leaves open non-HLA immune pathways in paraneoplastic syndromes.
We compared the human leukocyte antigen alleles found in a group of 17 patients with small-cell lung cancer (SCLC), paraneoplastic neurologic syndromes (PNS), and high titers of anti-Hu autoantibodies with those in 30 patients with SCLC but no PNS and no anti-Hu antibodies (control group). There was no difference between the two groups, suggesting that specific haplotypes are not required for the development of the "anti-Hu syndrome."
No takes yet. Share an insight, caveat, or question.
Uchuya et al. (1998) conducted a case-control in Small-cell lung cancer with anti-Hu syndrome (n=47). Human leukocyte antigen (HLA) alleles vs. SCLC patients without PNS and no anti-Hu antibodies was evaluated on Difference in human leukocyte antigen alleles. Human leukocyte antigen alleles showed no difference between small-cell lung cancer patients with and without the anti-Hu syndrome, suggesting specific haplotypes are not required for its development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: